Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naranie Shanmuganathan

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Expert Review of Hematology|July 10, 2025
How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?Jessica Sia, Naranie Shanmuganathan
Hemasphere|March 21, 2022
NGS in CML - New standard diagnostic procedure?Susan Branford, Naranie Shanmuganathan
British Journal of Haematology|September 18, 2024
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemiaNaranie Shanmuganathan, Andrew Grigg
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie Shanmuganathan
Current Hematologic Malignancy Reports|November 8, 2019
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Naranie Shanmuganathan, Susan Branford
British Journal of Haematology|June 14, 2021
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencingNaranie Shanmuganathan, Susan Branford
Hematology. American Society of Hematology. Education Program|December 4, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Blood|February 21, 2020
What's NEXT for CML-NGS mutation screeningNaranie Shanmuganathan, Timothy P Hughes
Current Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P Hughes
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Expert Review of Hematology|July 10, 2025
How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?Jessica Sia, Naranie Shanmuganathan
Hemasphere|March 21, 2022
NGS in CML - New standard diagnostic procedure?Susan Branford, Naranie Shanmuganathan
British Journal of Haematology|September 18, 2024
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemiaNaranie Shanmuganathan, Andrew Grigg
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie Shanmuganathan
Current Hematologic Malignancy Reports|November 8, 2019
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Naranie Shanmuganathan, Susan Branford
British Journal of Haematology|June 14, 2021
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencingNaranie Shanmuganathan, Susan Branford
Hematology. American Society of Hematology. Education Program|December 4, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Blood|February 21, 2020
What's NEXT for CML-NGS mutation screeningNaranie Shanmuganathan, Timothy P Hughes
Current Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P Hughes
Pageof 6